ICPT logo

Intercept Pharmaceuticals, Inc.

ICPT

ICPT: Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

more

Show ICPT Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of ICPT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ICPT's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

  • $30,000 Jul 14, 2023 Issue: Health Issues
  • $30,000 Apr 18, 2023 Issue: Health Issues
  • $30,000 Jan 20, 2023 Issue: Health Issues
  • $30,000 Oct 14, 2022 Issue: Health Issues
  • $20,000 Aug 26, 2022 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Isotopically labeled bile acid derivatives Oct. 18, 2022
  • Patent Title: Medicine obtained by combining fxr agonist and arb Aug. 23, 2022
  • Patent Title: Oral preparation of obeticholic acid Aug. 16, 2022
  • Patent Title: Tgr5 modulators and methods of use thereof May. 31, 2022
  • Patent Title: 3-desoxy derivative and pharmaceutical compositions thereof May. 03, 2022
  • Patent Title: Pharmaceutical compositions for combination therapy Apr. 26, 2022
  • Patent Title: Methods and intermediates for the preparation bile acid derivatives Jul. 27, 2021
  • Patent Title: Methods and intermediates for the preparation of bile acid derivatives Jul. 20, 2021
  • Patent Title: Farnesoid x receptor modulators Jun. 15, 2021
  • Patent Title: Farnesoid x receptor modulators May. 11, 2021
  • Patent Title: Treatment of fibrosis using fxr ligands Apr. 27, 2021
  • Patent Title: Fxr agonist compositions for combination therapy Jan. 19, 2021
  • Patent Title: 3-desoxy derivative and pharmaceutical compositions thereof Oct. 27, 2020
  • Patent Title: Steroids as agonists for fxr Oct. 27, 2020
  • Patent Title: Tgr5 modulators and methods of use thereof Oct. 13, 2020
  • Patent Title: Compositions of obeticholic acid and methods of use Sep. 01, 2020
  • Patent Title: Compositions of obeticholic acid and methods of use Aug. 25, 2020
  • Patent Title: Compositions of obeticholic acid and methods of use May. 12, 2020
  • Patent Title: Methods for the preparation of obeticholic acid and derivatives thereof Feb. 04, 2020
  • Patent Title: Methods of promoting hepatic regeneration Feb. 04, 2020
  • Patent Title: Farnesoid x receptor modulators Jan. 14, 2020
  • Patent Title: Steroids as agonists for fxr Sep. 24, 2019
  • Patent Title: Methods for preparation of bile acids and derivatives thereof Sep. 17, 2019
  • Patent Title: Methods of treating cancer Aug. 06, 2019
  • Patent Title: Treatment of fibrosis using fxr ligands Apr. 16, 2019
  • Patent Title: Process for preparing bile acid derivatives Feb. 12, 2019
  • Patent Title: Preparation and uses of obeticholic acid Jan. 08, 2019
  • Patent Title: Preparation and uses of obeticholic acid Dec. 18, 2018
  • Patent Title: Compositions of obeticholic acid and methods of use Aug. 21, 2018
  • Patent Title: Preparation and uses of obeticholic acid Aug. 14, 2018
  • Patent Title: Preparation and uses of obeticholic acid May. 29, 2018
  • Patent Title: Process for preparing bile acid derivatives Oct. 03, 2017
  • Patent Title: Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions Sep. 19, 2017
  • Patent Title: Steroids as agonists for fxr Aug. 15, 2017
  • Patent Title: Preparation and uses of obeticholic acid Aug. 15, 2017
  • Patent Title: Tgr5 modulators and methods of use thereof May. 16, 2017
  • Patent Title: Farnesoid x receptor modulators Apr. 04, 2017
  • Patent Title: Tgr5 modulators and methods of use thereof Jan. 10, 2017
  • Patent Title: Treatment of fibrosis using fxr ligands Nov. 22, 2016
  • Patent Title: Tgr5 modulators and methods of use thereof Jan. 26, 2016
  • Patent Title: Preparation and uses of obeticholic acid Jan. 19, 2016
  • Patent Title: Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions Jul. 28, 2015
  • Patent Title: Tgr5 modulators and methods of use thereof Apr. 07, 2015
  • Patent Title: Steroids as agonists for fxr Mar. 03, 2015
  • Patent Title: Tgr5 modulators and methods of use thereof Aug. 05, 2014
  • Patent Title: Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions Oct. 01, 2013
  • Patent Title: Tgr5 modulators and methods of use thereof May. 21, 2013
  • Patent Title: 23-substituted bile acids as tgr5 modulators and methods of use thereof Apr. 02, 2013
  • Patent Title: Steroids as agonists for fxr Feb. 19, 2013
  • Patent Title: Tgr5 modulators and methods of use thereof Feb. 14, 2012
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ICPT in WallStreetBets Daily Discussion

ICPT News

Recent insights relating to ICPT

CNBC Recommendations

Recent picks made for ICPT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ICPT

Corporate Flights

Flights by private jets registered to ICPT